Cannabis Report
Home > Boards > US Listed > Medical - Healthcare > Sanofi-Aventis (sny)

A bump on the road but still going!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Trend-Setter Member Profile
 
Followed By 3
Posts 487
Boards Moderated 0
Alias Born 07/19/13
160x600 placeholder
New England Journal of Medicine Publishes Final Results from Innovative Phase 2 Study Showing Vaccines Can Reduce Rate of Sus... PR Newswire (US) - 7/11/2018 8:23:00 PM
Sanofi dénonce la recommandation défavorable de l'ACMTS qui pourrait limiter les options de traitement pour les Canadiens a... PR Newswire (Canada) - 7/10/2018 7:04:00 AM
Sanofi denounces CADTH negative recommendation that could limit treatment options for Canadians with atopic dermatitis PR Newswire (Canada) - 7/10/2018 7:02:00 AM
Sanofi's Mourenx Plant to Remain Shut Until Emissions, Safety Requirements Met Dow Jones News - 7/10/2018 5:10:00 AM
Sanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China PR Newswire (US) - 7/2/2018 6:00:00 AM
Sanofi Finalizes Sale of Zentiva to Advent International for EUR1.9 Billion Dow Jones News - 6/28/2018 1:45:00 AM
Sanofi presents results from the first head-to-head study comparing Toujeo® to insulin degludec PR Newswire (US) - 6/25/2018 8:01:00 AM
NICE Recommends Sanofi's New Treatment Dupixent(R) ▼ (dupilumab) for Adults with Moderate to Severe Atopic Dermatitis in En... PR Newswire (US) - 6/22/2018 2:00:00 AM
Sanofi Names Jean-Baptiste Chasseloup de Chatillon as CFO, Executive VP Dow Jones News - 6/19/2018 2:24:00 AM
Evotec Shares Jump After It Secures Sanofi Agreement Dow Jones News - 6/18/2018 5:43:00 AM
Les employeurs canadiens sous-estiment la proportion de leur effectif qui est atteint d'une maladie chronique et son incidenc... PR Newswire (Canada) - 6/13/2018 7:34:00 AM
Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact PR Newswire (Canada) - 6/13/2018 7:23:00 AM
New England Journal of Medicine Publishes Cemiplimab Trial Results in Advanced Cutaneous Squamous Cell Carcinoma[1] PR Newswire (US) - 6/5/2018 2:00:00 AM
New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous c... PR Newswire (US) - 6/4/2018 2:15:00 PM
Sanofi Says Average Net Price of Its Drugs Fell Last Year Dow Jones News - 6/1/2018 3:26:00 PM
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes GlobeNewswire Inc. - 5/22/2018 8:03:00 AM
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes PR Newswire (US) - 5/22/2018 8:01:00 AM
New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-sev... PR Newswire (US) - 5/21/2018 2:15:00 PM
Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic ... PR Newswire (US) - 5/16/2018 8:00:00 AM
Sanofi's Dupixent Drug Meets Endpoints for Atopic Dermatitis Treatment Dow Jones News - 5/16/2018 2:03:00 AM
It Affects Over 1.5 Million People in the UK. [1],[2] In a Survey, 80% Report that it Impacts their Mood, Mental Health and W... PR Newswire (US) - 5/15/2018 2:00:00 AM
Sanofi-Ablynx Deal Goes Ahead Dow Jones News - 5/14/2018 2:57:00 AM
ADRs End Lower Dow Jones News - 5/1/2018 5:26:00 PM
Regeneron and Sanofi Cut Price to Compete With Amgen -- Market Talk Dow Jones News - 5/1/2018 9:47:00 AM
Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable... PR Newswire (US) - 5/1/2018 7:00:00 AM
Trend-Setter   Wednesday, 01/03/18 04:27:02 PM
Re: Trend-Setter post# 79
Post # of 86 
A bump on the road but still going!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist